Description
Enfuvirtide · CAS 159519-65-0 · C204H301N51O64. UNII 19OWO1T3ZE. Hydrophobicity: -0.875.
Identification
| CAS Registry Number | 159519-65-0 |
|---|
| PubChem CID | 16130199 |
|---|
| Molecular formula | C204H301N51O64 |
|---|
| UNII (FDA) | 19OWO1T3ZE |
|---|
Computed Descriptors
| Molecular Weight | 4492 |
|---|
| XLogP3 | -14.7 |
|---|
| Hydrogen Bond Donor Count | 63 |
|---|
| Hydrogen Bond Acceptor Count | 67 |
|---|
| Rotatable Bond Count | 151 |
|---|
| Exact Mass | 4491.1933541 |
|---|
| Monoisotopic Mass | 4489.1866445 |
|---|
| Topological Polar Surface Area | 1900 |
|---|
| Heavy Atom Count | 319 |
|---|
| Formal Charge | 0 |
|---|
Physical & Chemical Properties
Physical description & handling notes
- White to off white amorphous solid
- Negligible solubility in pure water. In buffer pH 7.5, 85-142 mg/100 mL.
- Reconstituted solution should be stored under refrigeration at 2 to 8 °C (36 to 46 °F) and used within 24 hours.
- pKa = 4.25 (Glutamic acid side chains 5 in sequence); pKa = 10.5 (Lysine amino side chain 2 in sequence); pKa = 3.86 (Aspartic acid side chain 1 in sequence); pKa = 6.00 (Histidine side chain 1 in sequence)
- Parenteral: For injection: 108 mg Fuzeon (with sterile water for injection diluent), (Roche).
GHS Hazard Classification
| Reported hazard statements | H317 (100%) |
|---|
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
P261, P272, P280, P302+P352, P321, P333+P317, P362+P364, and P501 (click each P-code to see the statement)
Documented Uses
- Preparation ... D.P. Bolognesi et al, WO 94 28920; eidem, US 5464933 (1994, 1995 both to Duke University)
- Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). Enfuvirtide has not been associated with serum aminotransferase elevations during therapy or episodes of acute, clinically apparent liver injury.
- Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Fusion Inhibitors
- Subcutaneous injection of enfuvirtide has been associated with reactions at the site of administration, including mild to moderate pain/discomfort, induration, erythema, presence of nodules or cysts, pruritus, and ecchymosis, in up to 98% of patients. In clinical studies, injection site reactions occurred during the first week of therapy in 86% of patients; in most patients, the severity of these reactions did not change during the 24-week study. Individual injection site reactions persisted for longer than 7 days
- For more Drug Warnings (Complete) data for ENFUVIRTIDE (10 total), please visit the HSDB record page.
Synonyms
Enfuvirtide; Pentafuside; Fuzeon; DP178; DP-178; Enfuvirtida; CHEBI:608828; Fuzeon T-20; 19OWO1T3ZE; DTXSID20166672; peptide T20; T20, Peptide; enfuvirtidum; RefChem:55093; DTXCID8089163; J05AX07
Frequently Asked Questions
What are the CAS number and molecular formula of Enfuvirtide?
CAS 159519-65-0; molecular formula C204H301N51O64; molecular weight — g/mol.
What other names is Enfuvirtide known by?
Enfuvirtide, Pentafuside, Fuzeon, DP178, DP-178, Enfuvirtida.
Is Enfuvirtide classified as hazardous?
Hazard statements reported: H317.
What are the key physical properties of Enfuvirtide?
Hydrophobicity: -0.875.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.
